Podcasts about retirement trader

"We're in the platinum age of healthcare," - Dr. David Eifrig In the age of technology, healthcare is moving at the speed of light, with new research leading to the development of cures for everything from hair loss to new cancer therapies. In the coming years, your genetic code will be the key to unlocking your life potential to be over one hundred. With all of these advancements, there are emerging opportunities for investors in the healthcare market. Dr. David Eifrig started his career trading derivatives at Goldman Sachs for over a decade. In 1995, he decided to switch careers and left Wall Street to become a medical doctor becoming a board-eligible eye surgeon before landing at Stansberry Research, where he launched his Retirement Trader, Retirement Millionaire, and Prosperity Investor newsletters. He is also the author of five books, including The Living Cure: The Promise of Cancer Immunotherapy. He owns and produces his own wine at Eifrig Cellars LLC in northern Sonoma County, California. On this episode of The Wiggin Sessions, Dr. Eifrig joins me to discuss the platinum age of healthcare and the science of rapidly developing new therapies for everything from Alzheimer's to new genetic therapies for cancers. We discuss his predictions for where he sees healthcare going in the coming years and why your genetic code is the key to unlocking your potential to live to be one hundred or more. Listen in to learn insider secrets on what you should pay attention to as an individual and an investor to take advantage of this new era's rapid pace of discovery. Plus, he shares 2 of his healthcare picks for investors now and the biggest opportunity he's seen in any market. Key Takeaways Dr. Eifrig shares his journey from Wall Street to medicine, to combining health information with financial information through his newsletters Dr. Eifrig shares the most innovative things in the healthcare field right now How genetic profiles are helping doctors to create cures at a rapid-fire rate Where Big Pharma is focusing its attention right now Why genetic editing is the key to changing the average healthy lifespan of individuals How to use your genetic profile to stay up to date on the latest cures as they happen Dr. Eifrig shares how he and his team evaluate a healthcare company in order to determine its investment potential  How macroeconomic turmoil affects the healthcare industries How The Living Cure works by using your own cells to cure diseases Dr. Eifrig shares how he got into the wine business Connect with Dr. David Eifrig Dr. Eifrig on the Biggest Opportunity He Has Ever Seen in Any Market Dr. Eifrig on LinkedIn Connect with Addison Wiggin Consilience Financial Be sure to follow The Wiggin Sessions on your socials. You can find me on— Facebook @thewigginsessions Instagram @thewigginsessions Twitter @WigginSessions Resources Stansberry Research Retirement Trader Retirement Millionaire Prosperity Investor The Living Cure Eifrig Cellars LLC Illumina Editas Medicine Bill Bonner— The Crisis That Could Bring Down the American Empire Share the Wiggin Sessions on Apple Podcasts

This week, for the first time ever, Dan is featuring two guests on the show. Regular Investor Hour listeners should instantly recognize their names... Dr. David "Doc" Eifrig and Thomas Carroll.  Doc is an MBA, former Wall Street trader, published author, and medical doctor. (Plus, he even owns a winery.) In the Stansberry Research universe, he's the editor of Retirement Millionaire, Retirement Trader, Income Intelligence, Advanced Options, and the Health & Wealth Bulletin.  Tom was once named by Fortune magazine as the No. 1 health care analyst in the U.S. His research has been referenced by health care publications and institutional investors alike, along with CNBC, Bloomberg, and Fox Business. And Stansberry readers know him for his investment expertise in the emerging legal cannabis market. In today's interview, Tom says health care is the most promising and important economic sector of the market right now... Some people think it's a boring sector to invest in, but I think it's paramount for every investor – for anyone who takes a self-directed or a primary interest in how they're investing their money. They have to know and have some exposure to health care. It's a $4 trillion market that's only getting bigger. It goes up each and every year.  That's why he and Doc recently joined forces with John Engel – a former biochemist and one of Stansberry's resident biotechnology experts – to launch a new research product, Prosperity Investor. In this monthly advisory, the powerhouse team shares the best of the current industry stalwarts, next-generation medicine, emerging digital-health solutions, and much more. On the show, Doc and Tom also share some of the biggest trends in the space. You'll hear about advancements in telemedicine, breakthrough research in immunology, and navigating the complexities in managed care. Lastly, you won't want to miss the duo's final bit of advice for listeners... a nugget that Dan – once he removed his jaw from the floor – called "one of the best, most actionable answers ever given in the history of the show."

This week, for the first time ever, Dan is featuring two guests on the show. Regular Investor Hour listeners should instantly recognize their names... Dr. David "Doc" Eifrig and Thomas Carroll.  Doc is an MBA, former Wall Street trader, published author, and medical doctor. (Plus, he even owns a winery.) In the Stansberry Research universe, he's the editor of Retirement Millionaire, Retirement Trader, Income Intelligence, Advanced Options, and the Health & Wealth Bulletin.  Tom was once named by Fortune magazine as the No. 1 health care analyst in the U.S. His research has been referenced by health care publications and institutional investors alike, along with CNBC, Bloomberg, and Fox Business. And Stansberry readers know him for his investment expertise in the emerging legal cannabis market. In today's interview, Tom says health care is the most promising and important economic sector of the market right now... Some people think it's a boring sector to invest in, but I think it's paramount for every investor – for anyone who takes a self-directed or a primary interest in how they're investing their money. They have to know and have some exposure to health care. It's a $4 trillion market that's only getting bigger. It goes up each and every year.  That's why he and Doc recently joined forces with John Engel – a former biochemist and one of Stansberry's resident biotechnology experts – to launch a new research product, Prosperity Investor. In this monthly advisory, the powerhouse team shares the best of the current industry stalwarts, next-generation medicine, emerging digital-health solutions, and much more. On the show, Doc and Tom also share some of the biggest trends in the space. You'll hear about advancements in telemedicine, breakthrough research in immunology, and navigating the complexities in managed care. Lastly, you won't want to miss the duo's final bit of advice for listeners... a nugget that Dan – once he removed his jaw from the floor – called "one of the best, most actionable answers ever given in the history of the show."

A dwindling middle class coupled with increasing prices for gas, food, lumber, homes and more - Trish worries that the economy is on a runway to destruction, for most Americans. An hourglass economy with too many people on the bottom of the economic spectrum and the same at the top. Where is the middle class?  Trish welcomes in Stansberry Research's Dr. David Eifrig - Publisher Retirement Millionaire, which shows readers how to live a millionaire lifestyle on less money than you'd imagine possible. He's gone on to launch Retirement Trader, which uses options to help people construct safe, reliable income streams… Income Intelligence, the most comprehensive monthly review we know of the universe of income investments… and Advanced Options, which applies options trading to the stocks that are recommended by Stansberry Research to earn bigger gains.  Doc's track record continues to amaze as many of his Retirement Trader readers know, with his documented 136 consecutive winners picked.   Doc and Trish are brutally aware of real inflation, something you won't hear from the mainstream and certainly not government officials and the central banks… Trish and Dr. Eifrig discuss the U.S. dollar and lack of purchasing power, plus they give retirement insights that helps safeguard from the increasingly centralized economy. Learn what percentage of your portfolio should be in Gold. Do Corporate Bonds have a part? What about US Treasures? Doc explains. Does the 60/40 asset allocation model still hold up? The important topics in today's climate with one of the most renowned Retirement Experts in the world.

In episode 143 we welcome Dr. David Eifrig. David begins by going through his background and pathway to finance. He first discovered his interest in investing through the occasional Barron’s issue, and understood he didn’t want to follow in his father’s footsteps in medicine, moving on to Kellogg for business school before moving on to Wall Street. He describes that while working in finance, he decided to pursue science and medical school and ultimately helped build a business that was sold to Roche. While in residency, he began writing and that launched him into newsletter writing. Meb then asks David to describe his publications, Retirement Millionaire, Retirement Trader, Income Intelligence, and the newly launched Advanced Options. Meb asks David about how he thinks about value and price declines. David responds with some background on how he prefers to teach investing, and provides a simple framework for thinking about price and value. After a quick discussion of the closed-end fund space, the conversation shifts to what looks interesting right now. David discusses Altria, and their exposure to the vaping market and the marijuana industry as well as preferred shares. The pair then expands with a discussion about the current interest rate and inflationary environment after an interesting example from David. David also gets into the use of stop losses, having a plan, and the mindset of having an idea of when to sell. He mentions that he thinks about structuring portfolio positions such that losses on one single position won’t significantly impact the overall portfolio. The conversation then shifts gears into some lifestyle suggestions, David’s experience as a winemaker, and David’s best and worst trades. All this and more in episode 143.

In the wake of Tuesday’s market carnage, with almost all of the major indices losing 3% of their value, Dan sees a rough slog ahead for almost all U.S. stocks. By any reasonable metric, stocks are a bad deal – but a few diamonds exist in the rough. Of course, there are not just bad deals to be found, but also outright land mines for investors, as is the case with GE, whose rotten pension dilemma Dan breaks down this week for listeners. Later on, Dan and Buck are joined by Dr. David (Doc) Eifrig and Stansberry Senior Analyst Matt Weinschenk. Doc has a storied past working for years trading derivatives at Goldman Sachs before leaving Wall Street to become an eye doctor before finally joining Stansberry in 2008. Matt has spent over a decade as an investment analyst and six of those have been here with Doc. Doc’s Retirement Trader options trading service has achieved a 95% success rate since its debut in 2010, a time spanning hundreds of investment recommendations made in all sorts of market conditions. But now, he says it’s time to think even bigger. In unleashing his newest, upgraded options trading service, Advanced Options, Doc, Matt, and the rest of their team are unveiling a service that’s designed to magnify the upside of some of Stansberry Research’s biggest wins, while helping to cut risk to the bone. We think you’ll want to keep an eye out for Doc’s special offer made at the end – which includes two years of Advanced Options, one year of Retirement Millionaire, and one full year of True Wealth and Stansberry’s Investment Advisory.  For more on Dr Eifrigs options course go to:  www.investorhouroptions.com

Dan Ferris, editor of the Extreme Value newsletter at Stansberry Research, explains deep value investing.  He shows us exactly what metrics he uses to value stocks and how investors can avoid value traps.  Dan also shares some of his favorite stocks to buy.   Dr. David Eifrig, editor of the Retirement Millionaire and Retirement Trader newsletters at Stansberry Research, outlines several key steps young investors need to take to become millionaires by the time they retire. Dr. Eifrig then explains why investors should not be scared to own stocks.  He also shares some of his favorite investment ideas.

This week, Dr. David Eifrig, editor of Retirement Millionaire, Retirement Trader, and Income Intelligence, joins Stansberry Radio.Aaron starts the show by asking Doc to comment on his overall macro picture right now.Most people turn to the mainstream headlines to find out how the economy is doing... Find out how Doc gets insight to the economy from simply asking a taxi cab driver some questions... You'll hear him list several indicators that the economy is doing better that are undetected by most people.And... there is one fundamental principle in finance that investors should think about EVERY single day... and Doc reveals it here!Plus, don't miss out on this... Doc shares his favorite stocks to buy right now.

This week, Dr. David Eifrig, editor of Retirement Millionaire, Income Intelligence, and Retirement Trader, joins S&A Investor Radio.At one point,  Doc picked 136 winning trades in a row... Now he reveals his top trading secrets.Plus, Doc is hosting a webinar on Thursday night for investors interested in generating more income for their retirement portfolios. Frank tells listeners how to sign-up for free during this special interview. Click here to learn more.Frank answers a bunch of listener e-mails.Plus, don't miss his educational segment. Frank tells you what he predicts to be the best-performing sector for 2014... You should be loading up on these stocks within this sector before they make this special announcement... Enjoy.

This week, Dr. David Eifrig, editor of Retirement Millionaire, Retirement Trader, and Income Intelligence joins Stansberry Radio.As we all know... Porter and Doc don't agree on a lot of things... Doc is seeing a cyclical recovery on its way. If you take a step back and look at the overall trend, you will see we are breaking free of a recession and are on an upswing.Aaron asks Doc to comment on his current World Dominating Dividend Growers in his portfolio.Find out why right now might not be the best time to get into these types of stocks... They also break down Doc's newest product, Income Intelligence, a newsletter that gives you the opportunity to learn how to earn high yields on safe investments and understand all the financial forces affecting your income.Hopefully you are paying attention, because an Income Intelligence pick is revealed.Subscribers pay hundreds of dollars for Doc's recommendations… Here, you get one for free.And... for all our health nuts out there, Doc shares some great tips, including three medical tests that are completely unnecessary.

This week, I interview bestselling author James Altucherand Dr. David “Doc” Eifrig, editor of Retirement Millionaire and Retirement Trader.  

Dr. David Eifrig, editor of the Retirement Trader newsletter, talks about his streak of closing out 61 straight winning trades. He discusses his proprietary trading strategies - and why small-caps should be on everyone's radar.

"Doc" Eifrig, editor of S&A's Retirement Millionaire and Retirement Trader advisories, joins Stansberry Radio this week to talk about his unprecedented 55-for-55 track record... and what he looks for in an options trade.

Dr. David Eifrig, editor of S&A’s Retirement Trader newsletter, talks about his near perfect track record for picking stocks in 2011.  Frank breaks down Intel and Best Buy’s latest earnings warnings – and what it means for the tech sector.

Dr David Eifrig, editor of the Retirement Trader newsletter, shares several of his conservative trading strategies. Michael Comeau, tech writer at Minyanville, tells us why you should be buying Apple right now.